Tuberculosis risk among patients with systemic diseases;Risque de tuberculose au cours des maladies systémiques

Presse Medicale

Volumn 38, Issue 2, 2009, Pages 274-290

  Ben m'rad, Mona ^a   Gherissi, Dalenda ^b   Mouthon, Luc ^b   Salmon Céron, Dominique ^b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CHEMOPROPHYLAXIS; EVALUATION; EXTRAPULMONARY TUBERCULOSIS; INFECTION RATE; INFECTION RISK; LUNG TUBERCULOSIS; MILIARY TUBERCULOSIS; PATIENT ASSESSMENT; REINFECTION; RHEUMATIC DISEASE; SCREENING TEST; SHORT SURVEY; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; TUBERCULIN TEST;

ANTIBODIES, MONOCLONAL; ANTITUBERCULAR AGENTS; CYCLOPHOSPHAMIDE; CYCLOSPORINE; FRANCE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; JAPAN; MYCOPHENOLIC ACID; RHEUMATIC DISEASES; RISK FACTORS; SPAIN; SWEDEN; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 58949095741     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2008.11.009     Document Type: Short Survey

References (79)

1. th ed. (2005), McGraw-Hill, New York 953-966
2. Frieden T.R., Sterling T.R., Munsiff S.S., Watt C.J., and Dye C. Tuberculosis. Lancet 362 (2003) 887-899
3. Behr M.A., Warren S.A., Salamon H., Hopewell P.C., Ponce de Leon A., Daley C.L., et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 353 (1999) 444-449
4. Schluger N.W., and Rom W.N. The host immune response to tuberculosis. Am J Respir Crit Care Med 157 (1998) 679-691
5. WHO. Global tuberculosis control: Surveillance, planning, financing. WHO report.. Geneva: World health organization, 2006: http://www.who.int/tb/publications/global_report/2006/download_centre/en /index.html.
6. Antoine D, Che D. Les cas de tuberculose maladie déclarés en France en 2006. Bulletin épidémiologique hebdomadaire 2008;n°10-11: http://www.invs.sante.fr/Beh/.
7. Jick S.S., Lieberman E.S., Rahman M.U., and Choi H.K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55 (2006) 19-26
8. Schatz M., Patterson R., Kloner R., and Falk J. The prevalence of tuberculosis and positive skin tests in a steroid-treated asthmatic population. Ann Intern Med 84 (1976) 261-265
9. Alcaïs A., Fieschi C., Abel L., and Casanova J.L. Tuberculosis in children and adults: two distinct genetic diseases. J Exp Med 202 (2005) 1617-1621
10. Wilkinson R.J., Llewelyn M., Toossi Z., Patel P., Pasvol G., Lalvani A., et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 355 (2000) 618-621
11. Martineau A.R., Wilkinson R.J., Wilkinson K.A., Newton S.M., Kampmann B., Hall B.M., et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 176 (2007) 208-213
12. Falagas M.E., Voidonikola P.T., and Angelousi A.G. Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int J Antimicrob Agents 30 (2007) 477-486
13. Erdozain J.G., Ruiz-Irastorza G., Egurbide M.V., Martinez-Berriotxoa A., and Aguirre C. High risk of tuberculosis in systemic lupus erythematosus?. Lupus 15 (2006) 232-235
14. Marie I., Hachulla E., Chérin P., Hellot M.F., Herson S., Levesque H., et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 53 (2005) 155-165
15. Mok M.Y., Lo Y., Chan T.M., Wong W.S., and Lau C.S. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. J Rheumatol 32 (2005) 609-615
16. Sayarlioglu M., Inanc M., Kamali S., Cefle A., Karaman O., Gul A., et al. Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus 13 (2004) 274-278
17. Tam L.S., Li E.K., Wong S.M., and Szeto C.C. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol 31 (2002) 296-300
18. Yun J.E., Lee S.W., Kim T.H., Jun J.B., Jung S., Bae S.C., et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol 20 (2002) 127-132
19. Agrawal P.N., Gupta D., Aggarwal A.N., and Behera D. Incidence of tuberculosis among patients receiving treatment with oral corticosteroids. J Assoc physicians India 48 (2000) 881-884
20. Hernández-Cruz B., Sifuentes-Osornio J., Ponce-de-León-Rosales S., Ponce-de-León-Garduño A., and Díaz-Jouanen E. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol 17 (1999) 289-296
21. Kim H.Y., Im Y., Goo J.M., Lee J.K., Song J.W., and Kim S.K. Pulmonary tuberculosis in patients with systemic lupus erythematosus. Am J Roentgenol 173 (1999) 1639-1642
22. Hou C.L., Tsai Y.C., Chen L.C., and Huang J.L. Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extra-pulmonary infection compared. Clin Rheumatol 27 (2008) 557-563
23. Andonopoulos A., Safridi C., Karokis D., and Bounas A. Is a purified protein derivative skin test and subsequent antituberculous chemoprophylaxis really necessary in systemic rheumatic disease patients receiving corticosteroids?. Clin rheumatol 18 (1998) 181-185
24. Balakrishnan C., Mangat G., Mittal G., and Joshi V.R. Tuberculosis infection in patients with systemic lupus erythematosus. J Assoc physicians India 46 (1998) 682-683
25. Victorio-Navarra S.T., Dy E.E., Arroyo C.G., and Torralba T.P. Tuberculosis among Filipino patients with systemic lupus erythematosus. Semin Arthritis Rheum 26 (1996) 628-634
26. Feng P.H., and Tan T.H. Tuberculosis in patients with systemic lupus erythematosus. Ann Rheum Dis 41 (1982) 11-14
27. Davies S.D., Yankelevitz D.F., Williams T., and Henschke C. Pulmonary tuberculosis in immunocompromised hosts: epidemiological, clinical and radiologic assessment. Semin Roentgenol 28 (1993) 119-130
28. Alarcón G.S. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin N Am 20 (2006) 849-875
29. Caporali R., Caprioli M., Bobbio-Pallavicini F., and Montecucco C. DMARDS and infections in rheumatoid arthritis. Autoimmunity Rev 8 (2008) 139-143
30. Chen Y., Chu S.H., Wie T.H., Chiang Y.J., Wu C.T., and Chen H.W. Does mycophenolate mofetil increase the incidence of infections in stable renal transplant recipients initially treated with a two-drug regimen?. Transplant Proc 36 (2004) 2122-2123
31. Johnson D.W., Nicol D.L., Purdie D.M., Preston J.M., Brown A.M., Hawley C.M., et al. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients?. Transplantation 73 (2002) 1158-1163
32. Rungruanghiranya S., Ekpanyaskul C., Jirasiritum S., Nilthong C., Pipatpanawong K., and Mavichak V. Tuberculosis in Thai renal transplant recipients: a 15-year experience. Transplant Proc 40 (2008) 2376-2379
33. Hočevar A., Rozman B., Praprotnik B., Lestan B., Eržen D., Petric V., et al. Leflunomide-associated tuberculosis?. Rheumatology (Oxford) 45 (2006) 228-229
34. Pagnoux C., and Teixeira L. Granulomatose de Wegener. Presse Med 36 (2007) 861-874
35. Guillevin L., and Pagnoux C. Traitement des vascularites systémiques associées aux ANCA. Presse Med 35 (2007) 922-927
36. Lügering A., Schmidt M., Lügering N., Pauels H.-G., Domschke W., and Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 (2001) 1145-1157
37. Van den Brande J.M., Braat H., Van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemacker I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
38. Keane J., Gershon S., Pharm D., and Wise R.P. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing. New Engl J Med 345 (2001) 1098-1104
39. F. Tubach, D. Salmon, P. Ravaud, T.Lequerré, P. Goupille, T. Shaeverbeke, et al. The risk of tuberculosis with anti TNF is higher with monoclonal antibodies than with the soluble receptor : results of the French-3 year prospective observatory. Annual congress of the European League Against Rheumatism, 2008, abstract OP-0014.
40. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Cöster L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 (2005) 1986-1992
41. Gomez-Reino J.J., Carmona L., Valverdo V.R., Mola E.M., and Montero M.D. Treatment of rheumatoid arthritis associated with tumor necrosis factor inhibitors may predispose to significant increase of tuberculosis risk. Arthritis Rheum 48 (2005) 2122-2127
42. Burr M.L., Malaviya A.P., Gaston J.H., Carmichael A.J., and Östör A.J. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology (Oxford) 47 (2008) 738-739
43. Jung N., Owczarczyk, Hellmann M., Lehmann C., Fätkenheuer G., Hallek M., et al. Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology (Oxford) 47 (2008) 933-936
44. Ilgazli A., Boyaci H., Basyigit I., and Yildiz F. Extra-pulmonary tuberculosis: clinical and epidemiologic spectrum of 636 cases. Arch Med Res 35 (2004) 435-441
45. Cheng V.C., Ho P.L., Lee R.A., Chan K.S., Chan K.K., Woo P.C., et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV patients. Eur J Clin Microbiol Infect Dis 21 (2002) 803-809
46. Pryor B.D., Bologna S.G., and Kahl L.E. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39 (1996) 1475-1482
47. Juárez M., Misischia R., and Alarcón G.S. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin North Am 29 (2003) 163-184
48. Marie I. Infections au cours des polymyosites et des dermatomyosites. Presse Med 38 (2009) 303-316
49. Bussone G., Berezné A., and Mouthon L. Complications infectieuses de la sclérodermie systémique. Presse Med 38 (2009) 291-302
50. Lee C.H., Shim J.C., and Lee Y.W. Tuberculous fasciitis in scleroderma. Clin Rheumatol 23 (2004) 66-68
51. Cowie R.L. Slicia-dust-exposed mine workers with scleroderma (systemic sclerosis). Chest 92 (1987) 260-262
52. Rossman M.D., and Kreider M.E. Lessons learned from ACCESS (a case controlled etiologic study of sarcoidosis). Proc Am Thorac Soc 4 (2007) 246-251
53. Inui N., Suda T., and Chida K. Use of the QuantiFERON-tuberculose Gold test in Japanese patients with sarcoidosis. Respir Med 102 (2008) 313-315
54. Papaetis G.S., Pefanis A., Solomon S., Tsangarakis I., Orphanidou D., and Achimastos A. Asymptomatic stage I sarcoidosis complicated by pulmonary tuberculosis: a case report. J Med Case Reports 2 (2008) 226
55. Kerbouch J.F., Clavier J., Zabre C., Gouva S., and Mottier D. A propos d'un nouveau cas d'association sarcoidose tuberculose ou les rapports intimes entre les deux maladies. Rev Pneumol Clin 43 (1987) 46-53
56. Dhote R, Abad S, Valeyre D. Risque infectieux au cours de la sarcoïdose. Presse Med 2009 (dans ce numéro).
57. Guillevin L., Pagnoux C., and Guilpain P. Classification des vascularites systémiques. Presse Med 36 (2007) 845-853
58. Mwipatayi B.P., Jeffery P.C., Beningfield S.J., Matley P.J., Naidoo N.G., Kalla A.A., et al. Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg 75 (2005) 110-117
59. Kerr G.S., Hallahan C.W., Giordano J., Leavitt R.Y., Fauci A.S., Rottem M., et al. Takayasu arteritis. Ann Intern Med 120 (1994) 919-929
60. Numano F., Kobayashi Y., Maruyama Y., Kakuta T., Miyata T., and Kishi Y. Takayasu's arteritis: clinical characteristics and the role of genetic factors in ist pathogenesis. Vasc Med 1 (1996) 227-233
61. Hahn D., Thomson P.D., Kala U., Beale P.G., and Levin S.E. A review of Takayasu's arteritis in children in Gauteng, South Africa. Pediatr Nephrol 12 (1998) 668-675
62. McCulloch M., Andronikou S., Goddard E., Sinclair P., Lawrenson J., Mandelstam S., et al. Angiographic features of 26 children with Takayasu's arteritis. Pediatr Radiol 33 (2003) 230-235
63. Rose A.G., Halper J., and Factor S.M. Primary artriopathy in Takayasu's disease. Arch Pathol Lab Med 108 (1984) 644-648
64. Harris N.L., McNeely W.F., Shepard J.A., Ebelling S.H., Ellender S., and Peters C.C. Case Records of the Massachusetts General Hospital: Case 18-2002. N Engl J Med 246 (2002) 1892-1899
65. Flores-Suárez L.F., Cabiedes J., Villa A.R., Van der Woude F.J., and Alcocer-Varela J. Prevalence of antineutrophil cytoplasmic antibodies in patients with tuberculosis. Rheumatology (Oxford) 42 (2003) 223-229
66. Pradhan V.D., Badakere S.S., Ghosh K., and Pawar W. Spectrum of antineutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis overlaps with that of Wegener's granulomatosis. Indian J Med Sci 58 (2004) 283-288
67. Teixeira L., Mahr A., Jaureguy F., Noël L.H., Nunes H., Lefort A., et al. Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis. Rheumatology (Oxford) 44 (2005) 247-250
68. Bourgarit A., Le Toumelin P., Pagnoux C., Cohen P., Mahr A., Le Guern V., et al. Deaths occuring during the first year after treatment onset of polyarteritis nodosa, microscopic polyangeiitis and Churg-Strauss syndrome. A retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine 84 (2005) 323-330
69. Yamada T., Nakajima A., Inoue E., Tanaka E., Hara M., and Tomatsu T. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65 (2006) 1661-1663
70. Wolfe F., Flowers N., Anderson J., and Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50 (2004) 372-379
71. AFSSAPS. Recommandations nationales sur la prévention et la prise en charge des tuberculoses survenant sous anti-TNF. http://afssaps.sante.fr/htm/10/tnf/reco.pdf.
72. Salmon D., and Bricaire F. Quelle est la place actuelle de l'IDR à la tuberculine?. Presse Med 35 (2006) 1720-1722
73. Heym B., and Chinet T. Méthodes diagnostiques de l'infection tuberculeuse en 2007 : intradermoréaction à la tuberculine ou interferon-γ ?. Rev Med Int 28 (2007) 147-150
74. ®-TB Gold test for detecting Mycobacterium tuberculosis infection, United States: www.cdc.gov/mmwr/preview/mmwrhtml/rr5415a4.htm.
75. Matulis G., Jüni P., Villiger P.M., and Gadola S.D. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases-performances of a Mycobacterium tuberculosis antigen-specific interferon γ assay. Ann Rheum Dis 67 (2008) 84-90
76. Kobashi Y., Mouri K., Obase Y., Fukuda M., Miyashita N., and Oka M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J 30 (2007) 945-950
77. Gaitonde S., Pathan E., Sule A., Mittal G., and Joshi V.R. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 61 (2002) 251-253
78. Hernández-Cruz B., Ponce-de-León-Rosales S., Sifuentes-Osornio J., Ponce-de-León-Garduño A., and Díaz-Jouanen E. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case control study. Clin Exp Rheumatol 17 (1999) 81-87
79. Jonhson J.L., Okwera A., Hom D.L., Mayanga H., Mutuluuza Kityo C., Nsubuga P., et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected patients. AIDS 15 (2001) 2137-2147